Loading...
The University of Chicago Header Logo
Keywords
Last Name
Institution

Connection

Search Results to Anthony T. Reder

This is a "connection" page, showing the details of why an item matched the keywords from your search.

                     
                     

One or more keywords matched the following properties of Reder, Anthony T.

PropertyValue
overview Dr. Anthony Reder has a 30-year interest in multiple sclerosis. He has coauthored over 150 papers, plus abstracts and presentations, on multiple sclerosis and animal models of MS. His primary research interests are in the interaction between the central nervous system (CNS) and the cellular immune system, and in how the brain and immune system are altered by the drugs we use to treat MS. Professor Reder has an active lab studying many facets of the immune disruption in MS, and also the mechanism of action of interferon-beta, the most widely-used treatment for MS. They have recently found that there is a defect in the interferon signaling pathway in lymphocytes from progressive forms of MS. This may be why some patients with progressive MS do not respond clinically to interferon therapy. Dr. Reder and other faculty members at the University of Chicago have participated in the development of multiple new treatments for MS. These include the first biological therapy for MS, interferon-beta, plus other drugs including glatiramer (Copaxone), natalizumab (Tysabri), rituximab, ocrelizumab, estriol (the pregnancy hormone), and FTY720/fingolimod (Gilenya), plus drugs for pain in MS such as misoprostol. He has also evaluated IFN-? patients 21 years after the original pivotal trial, the effects of statins and vitamin D on IFN efficacy, Current clinical trials include promising new drugs for neuromyelitis optica (NMO) and progressive MS. He has trained a number of excellent MS fellows, funded by the US National MS Society. Prior fellows, Adil Javed, and as of Aug 1, Veronica Cipriani, are now on faculty at the U of Chicago. Dr. Javed defined a new variant of MS, CNS Sjögren’s disease, which requires different treatments than conventional MS. Dr. Reder is also kind to puppies.

One or more keywords matched the following items that are connected to Reder, Anthony T.

Item TypeName
Concept Interferon-beta
Academic Article Increased CD80(+) B cells in active multiple sclerosis and reversal by interferon beta-1b therapy.
Academic Article Mechanisms of action of interferon-beta in multiple sclerosis.
Academic Article Improved delayed visual reproduction test performance in multiple sclerosis patients receiving interferon beta-1b.
Academic Article Effects of an anti-IL-10 monoclonal antibody on rIFNbeta-1b-mediated immune modulation. Relevance to multiple sclerosis.
Academic Article Interferon beta-1b effects on cytokine mRNA in peripheral mononuclear cells in multiple sclerosis.
Academic Article Interferon-beta treatment does not elevate cortisol in multiple sclerosis.
Academic Article Monocyte activation in multiple sclerosis.
Academic Article Type I interferons inhibit interleukin-10 production in activated human monocytes and stimulate IL-10 in T cells: implications for Th1-mediated diseases.
Academic Article Injecting rationale into interferon-beta therapy.
Academic Article Longitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing-remitting multiple sclerosis.
Academic Article Safety and tolerability of interferon beta-1b in pediatric multiple sclerosis.
Academic Article Interferon-beta regulates cytokines and BDNF: greater effect in relapsing than in progressive multiple sclerosis.
Academic Article IFN-beta-regulated genes show abnormal expression in therapy-naïve relapsing-remitting MS mononuclear cells: gene expression analysis employing all reported protein-protein interactions.
Academic Article Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis.
Academic Article Long-term follow-up of the original interferon-beta1b trial in multiple sclerosis: design and lessons from a 16-year observational study.
Academic Article Analysis of clinical outcomes according to original treatment groups 16 years after the pivotal IFNB-1b trial.
Academic Article Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis.
Academic Article Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis.
Academic Article Fingolimod for the treatment of relapsing multiple sclerosis.
Academic Article Evidence-based medicine: promise and pitfalls.
Academic Article IFN-beta1b induces transient and variable gene expression in relapsing-remitting multiple sclerosis patients independent of neutralizing antibodies or changes in IFN receptor RNA expression.
Academic Article Interferon effects on interleukin-10 secretion. Mononuclear cell response to interleukin-10 is normal in multiple sclerosis patients.
Academic Article Immunoglobulin-like transcript 3, an inhibitor of T cell activation, is reduced on blood monocytes during multiple sclerosis relapses and is induced by interferon beta-1b.
Academic Article Relationship between early clinical characteristics and long term disability outcomes: 16 year cohort study (follow-up) of the pivotal interferon ß-1b trial in multiple sclerosis.
Academic Article Survival in MS: a randomized cohort study 21 years after the start of the pivotal IFNß-1b trial.
Academic Article IFN-gamma, IFN-beta, and PGE1 affect monokine secretion: relevance to monocyte activation in multiple sclerosis.
Academic Article Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.
Academic Article Cross-sectional study assessing long-term safety of interferon-beta-1b for relapsing-remitting MS.
Academic Article Low expression of interferon-stimulated genes in active multiple sclerosis is linked to subnormal phosphorylation of STAT1.
Academic Article Abnormal levels of interferon-gamma receptors in active multiple sclerosis are normalized by IFN-beta therapy: implications for control of apoptosis.
Academic Article Establishing long-term efficacy in chronic disease: use of recursive partitioning and propensity score adjustment to estimate outcome in MS.
Academic Article Treatment with interferon beta for multiple sclerosis.
Academic Article Urinary myelin basic protein-like material as a correlate of the progression of multiple sclerosis.
Academic Article Inhibition of interferon-beta responses in multiple sclerosis immune cells associated with high-dose statins.
Academic Article The effects of long-term interferon-beta-1b treatment on cognitive functioning in multiple sclerosis: a 16-year longitudinal study.
Academic Article Induction of a unique isoform of the NCOA7 oxidation resistance gene by interferon ß-1b.
Academic Article Immunomodulatory activity of interferon-beta.
Academic Article Interferon-beta-1b-induced short- and long-term signatures of treatment activity in multiple sclerosis.
Academic Article Predictive validity of NEDA in the 16- and 21-year follow-up from the pivotal trial of interferon beta-1b.
Academic Article Early MRI results and odds of attaining 'no evidence of disease activity' status in MS patients treated with interferon ß-1a in the EVIDENCE study.
Academic Article Vitamin D enhances responses to interferon-ß in MS.
Academic Article Interferon-ß corrects massive gene dysregulation in multiple sclerosis: Short-term and long-term effects on immune regulation and neuroprotection.
Academic Article COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies.
Academic Article Real-world propensity score comparison of treatment effectiveness of peginterferon beta-1a vs. subcutaneous interferon beta-1a, glatiramer acetate, and teriflunomide in patients with relapsing-remitting multiple sclerosis.
Academic Article Interferons and Multiple Sclerosis: Lessons from 25 Years of Clinical and Real-World Experience with Intramuscular Interferon Beta-1a (Avonex).

Search Criteria
  • Interferon beta